Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Eugene Swenson, MD, PhD
Alexion Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Clinical Trial Site
Vienna, Austria
- Clinical Trial Site
Heidelberg, Germany
- Clinical Trial Site
Warsaw, Poland
- Clinical Trial Site
Guildford, Surrey, United Kingdom
- Clinical Trial Site
Birmingham, United Kingdom
- Clinical Trial Site
Los Angeles, California, United States
- Clinical Trial Site
New Haven, Connecticut, United States
- Clinical Trial Site
Chicago, Illinois, United States
- Clinical Trial Site
Ann Arbor, Michigan, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Nov 2014
- Primary completion
- 27 Oct 2016
- Completion
- 7 Nov 2018
- Last update posted
- 29 Sept 2021
- Registered enrollment
- 29
- Registry id
- NCT02273596
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.